Alnylam Pharmaceuticals (ALNY) Cash from Operations (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Cash from Operations came in at 326724000.0 in Q2 2026, up 151.7% YoY from 129807000.0 in Q2 2025, and up 363.41% on a QoQ basis from 70504000.0 in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Cash from Operations (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Cash from Operations data on file, last reported at 326724000.0 in Q2 2026.
- Quarterly Cash from Operations rose 151.7% year-over-year to 326724000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 911813000.0 (up 2299.26% YoY) and the FY2025 annual result came in at 524080000.0, up 6405.1% from the prior year.
- Cash from Operations climbed to 326724000.0 in Q2 2026, from 70504000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 359412000.0 in Q3 2023 to a low of 171193000.0 in Q1 2022.
- A 5-year average of 26437666.67 and a median of 44390500.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations slumped 217.71% — and 2025, when it jumped 703.14%.
- Tracing ALNY's Cash from Operations over 5 years: stood at 131978000.0 in 2022, then soared by 77.42% to 29795000.0 in 2023, then tumbled by 217.71% to 94662000.0 in 2024, then jumped by 272.78% to 163555000.0 in 2025, then surged by 99.76% to 326724000.0 in 2026.
- The last three Cash from Operations figures came in at 326724000.0 (Q2 2026), 70504000.0 (Q1 2026), and 163555000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -270.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 326.72 Mn |
| Jun 30, 2026 | 326.72 Mn |
| Mar 31, 2026 | 70.50 Mn |
| Mar 31, 2026 | 70.50 Mn |
| Dec 31, 2025 | 163.56 Mn |
| Dec 31, 2025 | 163.56 Mn |
| Sep 30, 2025 | 325.11 Mn |
| Sep 30, 2025 | 325.11 Mn |
| Jun 30, 2025 | 155.73 Mn |
| Jun 30, 2025 | 155.73 Mn |
| Mar 31, 2025 | -120.31 Mn |
| Mar 31, 2025 | -120.31 Mn |
| Dec 31, 2024 | -94.66 Mn |
| Dec 31, 2024 | -94.66 Mn |
| Sep 30, 2024 | 43.71 Mn |
| Sep 30, 2024 | 43.71 Mn |
| Jun 30, 2024 | 124.16 Mn |
| Jun 30, 2024 | 124.16 Mn |
| Mar 31, 2024 | -81.52 Mn |
| Mar 31, 2024 | -81.52 Mn |